{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:26:59Z","timestamp":1790018819593,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.molimm.2014.05.001","type":"journal-article","created":{"date-parts":[[2014,5,24]],"date-time":"2014-05-24T09:46:08Z","timestamp":1400924768000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: Ethnic differences and potential new targets for therapeutic drugs"],"prefix":"10.1016","volume":"61","author":[{"given":"Beverly D.","family":"Lyn-Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-5597","authenticated-orcid":false,"given":"Jarren","family":"Oates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Treadwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Word","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hammons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2014.05.001_bib0005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signaling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molimm.2014.05.001_bib0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.molimm.2014.05.001_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/0961203305lu2102rr","article-title":"A toll for lupus","volume":"14","author":"Anders","year":"2005","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.molimm.2014.05.001_bib0020","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/eji.200737815","article-title":"Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms","volume":"37","author":"Barrat","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"5625","key":"10.1016\/j.molimm.2014.05.001_bib0025","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.1085536","article-title":"Toll-like receptor signaling pathways","volume":"300","author":"Barton","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.molimm.2014.05.001_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.smim.2006.12.005","article-title":"Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors","volume":"19","author":"Christensen","year":"2007","journal-title":"Semin. Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2014.05.001_bib0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1084\/jem.20050338","article-title":"Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus","volume":"202","author":"Christensen","year":"2005","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.molimm.2014.05.001_bib0040","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1073\/pnas.0701266104","article-title":"Three functional variants of IFN regulatory factor 5 define risk and protective haplotypes for human lupus","volume":"104","author":"Graham","year":"2007","journal-title":"PNAS"},{"issue":"265","key":"10.1016\/j.molimm.2014.05.001_bib0045","first-page":"680","article-title":"Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies","volume":"10","author":"Harley","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.molimm.2014.05.001_bib0050","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2014.05.001_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/498980","article-title":"Targeting Toll-like receptors for treatment of SLE","volume":"498980","author":"Horton","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.molimm.2014.05.001_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1189\/jlb.0310126","article-title":"Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis","volume":"88","author":"Huang","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molimm.2014.05.001_bib0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.1183021","article-title":"Regulation of adaptive immunity by the innate immune system","volume":"327","author":"Iwasaki","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.molimm.2014.05.001_bib0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","article-title":"TLR signaling","volume":"19","author":"Kawai","year":"2007","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.molimm.2014.05.001_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1443.020","article-title":"Toll-like receptor and RIG-1-like receptor signaling","volume":"1143","author":"Kawai","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"29","key":"10.1016\/j.molimm.2014.05.001_bib0080","doi-asserted-by":"crossref","first-page":"12061","DOI":"10.1073\/pnas.0905441106","article-title":"Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus","volume":"106","author":"Kono","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.molimm.2014.05.001_bib0085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/ar2321","article-title":"Toll-like receptors and innate immune responses in systemic lupus erythematosus","volume":"9","author":"Lafyatis","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molimm.2014.05.001_bib0090","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri1957","article-title":"A Toll-like receptor in systemic autoimmune diseases","volume":"6","author":"Marshak-Rothestein","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.molimm.2014.05.001_bib0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/gene.2009.39","article-title":"Recent insights into the genetic basis of systemic lupus erythematosus","volume":"10","author":"Moser","year":"2009","journal-title":"Genes Immun."},{"issue":"5","key":"10.1016\/j.molimm.2014.05.001_bib0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2079","article-title":"The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling","volume":"7","author":"O\u2019Neill","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molimm.2014.05.001_bib0105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1196\/annals.1337.028","article-title":"Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility","volume":"1037","author":"Park","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.molimm.2014.05.001_bib0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0971-6866.100750","article-title":"Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus","volume":"18","author":"Pradhan","year":"2012","journal-title":"Indian J. Hum. Genet."},{"issue":"9","key":"10.1016\/j.molimm.2014.05.001_bib0120","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/ard.2007.086421","article-title":"Type 1 interferons might form the link between Toll-like receptor 3\/7 and TLR4-mediatd synovial inflammation in rheumatoid arthritis (RA)","volume":"68","author":"Roelofs","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.molimm.2014.05.001_bib0125","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/ard.2007.086421","article-title":"Type I interferons might form the link between Toll-like receptor (TLR) 3\/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA)","volume":"68","author":"Roelofs","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molimm.2014.05.001_bib0130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.21571","article-title":"The type I interferon system in systemic lupus erythematosus","volume":"54","author":"Ronnblom","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molimm.2014.05.001_bib0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-065X.2008.00729.x","article-title":"Regulatory molecules required for nucleotide-sensing Toll-like receptors","volume":"227","author":"Saitoh","year":"2009","journal-title":"Immunol. Rev."},{"issue":"17","key":"10.1016\/j.molimm.2014.05.001_bib0140","doi-asserted-by":"crossref","first-page":"17005","DOI":"10.1074\/jbc.M412584200","article-title":"The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling","volume":"280","author":"Schoenemeyer","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.molimm.2014.05.001_bib0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4331\/wjbc.v2.i7.167","article-title":"Toll-like receptors are potential therapeutic targets in rheumatoid arthritis","volume":"2","author":"Shotorbani","year":"2011","journal-title":"World J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.molimm.2014.05.001_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxh186","article-title":"Toll-like receptors in innate immunity","volume":"17","author":"Takeda","year":"2005","journal-title":"Int. Immunol."},{"issue":"5633","key":"10.1016\/j.molimm.2014.05.001_bib0155","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.molimm.2014.05.001_bib0160","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-\u03b1\/\u00df-inducible genes and downstream effect in a phase I trial of an anti-interferon-\u03b1 monoclonal antibody in system lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589014000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589014000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T19:21:39Z","timestamp":1565464899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589014000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0161589014000972"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2014.05.001","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: Ethnic differences and potential new targets for therapeutic drugs","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2014.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}